Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NIPENT vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Hairy cell leukemia,Cutaneous T-cell lymphoma
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
5 mg/m2 intravenously over 20-30 minutes every 3 weeks.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal elimination half-life is approximately 5-8 hours in patients with normal renal function. Clinically, the half-life may be prolonged in renal impairment, requiring dose adjustments.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Primarily metabolized by the liver via deamination by adenosine deaminase (ADA).
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Primarily renal excretion; approximately 50-70% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination accounts for <5%.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Approximately 90-95% bound to serum albumin.
Approximately 20–30% bound to plasma proteins.
Volume of distribution (Vd) is approximately 0.4 L/kg, indicating distribution primarily into extracellular fluid.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Not applicable; Nipent is only administered intravenously with 100% bioavailability via that route. Oral bioavailability is negligible and not clinically relevant.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
Contraindicated if creatinine clearance < 60 m L/min. For Cl Cr 60-90 m L/min: reduce dose to 2.5 mg/m2. Not recommended if Cl Cr < 60 m L/min.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
No specific dose adjustment guidelines for Child-Pugh class A or B. Use caution in severe hepatic impairment (Child-Pugh class C) and consider dose reduction based on tolerability.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Safety and efficacy not established in pediatric patients <18 years. No recommended weight-based dosing.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustments recommended for elderly based on age alone; monitor renal function closely as older patients are more likely to have decreased creatinine clearance.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
WARNING: NIPENT (pentostatin) can cause severe bone marrow suppression, leading to neutropenia, thrombocytopenia, and anemia. Fatal hemorrhagic events and infections have occurred. Use with caution in patients with impaired renal function.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Bone marrow suppression: monitor blood counts regularly,Renal toxicity: assess renal function before and during therapy,Hepatotoxicity: monitor liver function tests,Pulmonary toxicity: observe for signs of pneumonitis,Embryofetal toxicity: advise patients of reproductive potential to use effective contraception,Increased risk of infection: avoid live vaccines
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Hypersensitivity to pentostatin or any component of the formulation,Severe hepatic impairment,Pregnancy (risk of fetal harm)
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
Grapefruit and grapefruit juice should be avoided due to potential CYP3A4 inhibition. No other significant food interactions are reported.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
Pregnancy Category D. First trimester: potential teratogenicity (based on animal studies and limited human data). Second and third trimesters: risk of fetal harm (e.g., myelosuppression, growth restriction).
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
Contraindicated during breastfeeding. M/P ratio unknown; pentostatin is excreted in human milk with potential for serious adverse reactions in nursing infants.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
No established safe dose; avoid use in pregnancy. If unavoidable, consider reduced dosing based on increased volume of distribution and renal clearance, but individualize with close monitoring for toxicity.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
Administer with aggressive pre-hydration (≥2L NS) and urine alkalinization to prevent nephrotoxicity. Monitor for severe myelosuppression, especially neutropenia. Consider leukapheresis for high-risk patients to prevent tumor lysis syndrome. Dose adjustment required for renal impairment (Cr Cl <60 m L/min).
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
Drink at least 2-3 liters of water daily to protect kidneys.,Report any unusual bleeding, bruising, or signs of infection (fever, sore throat) immediately.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during and for 6 months after therapy.,Do not receive live vaccines during treatment.,Report any new or worsening shortness of breath or chest pain.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NIPENT vs CLADRIBINE, answered by our medical review team.
NIPENT is a Antineoplastic Agent that works by Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NIPENT and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NIPENT is: 5 mg/m2 intravenously over 20-30 minutes every 3 weeks.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NIPENT and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NIPENT is classified as Category C. Pregnancy Category D. First trimester: potential teratogenicity (based on animal studies and limited human data). Second and third trimesters: risk of fetal harm (e.g., myelosuppre. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.